Janus Henderson Group PLC Travere Therapeutics, Inc. Transaction History
Janus Henderson Group PLC
- $194 Billion
- Q2 2025
A detailed history of Janus Henderson Group PLC transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Janus Henderson Group PLC holds 9,541,270 shares of TVTX stock, worth $166 Million. This represents 0.07% of its overall portfolio holdings.
Number of Shares
9,541,270
Previous 7,528,622
26.73%
Holding current value
$166 Million
Previous $135 Million
4.67%
% of portfolio
0.07%
Previous 0.08%
Shares
18 transactions
Others Institutions Holding TVTX
# of Institutions
242Shares Held
102MCall Options Held
1.79MPut Options Held
540K-
Armistice Capital, LLC New York, NY8.87MShares$154 Million2.42% of portfolio
-
Black Rock Inc. New York, NY7.64MShares$133 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.99MShares$104 Million0.0% of portfolio
-
Macquarie Group LTD Australia, C35.1MShares$88.7 Million0.1% of portfolio
-
State Street Corp Boston, MA3.48MShares$60.6 Million0.0% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $1.12B
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...